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Abstract
Background: Early definitive diagnosis and effective treatment are mandatory in rheumatoid arthritis (RA) as it can halt the disease 
progression and subsequent joints destruction.
Objective: To investigate the diagnostic and prognostic value of anti-mutated citrullinated vimentin (anti-MCV) and its correlation with 
disease activity, peripheral and axial skeleton affection in RA patients.
Patients and methods: A total of 123 patients with different rheumatic diseases were enrolled in a prospective-two year study at Ain 
Shams University hospital: 64 patients with RA and 59 patients with other rheumatic diseases as controls. RA patients were fulfilling 
the traditional and the new ACR/EULAR diagnostic criteria for RA. They have been followed up for two years. At baseline, all RA 
patients were subjected to: Clinical assessment of disease activity by taking full histories, general and local examination, measurement 
of 28 joint count of tender and swollen joints with calculation of disease activity score (DAS-28) for each patient. Complete blood count, 
erythrocytes sedimentation rate, C-reactive protein and rheumatoid factor titers were performed. Anti-MCV IgG immunoglobulins’ 
assay was performed at the study endpoint by ELISA. RA patients were then classified into; anti-MCV positive and anti-MCV negative 
groups for statistical comparison. Plain X-ray was performed on the peripheral joints and scored by the Simple Erosion Narrowing score 
(SEN-score). Magnetic Resonance Imaging (MRI) scans were carried out to 22 RA patients on cervical and lumbosacral regions.
Results: Anti-MCV antibodies were found to be of high sensitivity (79.6%) and specificity (96.6%) in diagnosing RA. The area under 
the curve was 0.893 at 95% confidence interval (CI), confers an odds ratio of 23.5. Anti-MCV positive RA patients had significantly 
higher DAS-28 and SEN-scores than anti-MCV negative patients; who were found to have more benign disease with lower incidence 
of erosions (P , 0.05). MRI scans revealed that; 17/22 (77%) had cervical joints involvement while, 8 (36%) had lumbo-sacral joint 
lesions (P , 0.05), both were correlated significantly with aggressive peripheral joint disease.
Conclusion: Anti-MCV antibodies are promising diagnostic and prognostic marker in RA, with high sensitivity and specificity. They 
may identify a subset of RA patients with aggressive early erosive disease. The axial skeleton—especially the cervical spine—could be 
affected in RA and this was correlated with aggressive peripheral joints’ disease. MRI scanning is a sensitive method for detecting axial 
skeleton involvement in RA, in attempt for better disease control and outcomes.
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Introduction
Rheumatoid arthritis (RA) is a heterogenous disease 
of multifactorial origin that has variable outcomes. 
Early definitive diagnosis is essential in RA patients, 
as they have a true chance for achieving a “cure” of the 
disease if they are treated early and aggressively in the 
“window of opportunity” period. However, this needs 
sensitive clinical and laboratory diagnostic tools.1
Recently, the diagnosis of RA has been substan- 
tially improved by the introduction of standardized 
immunoassays  for  the  detection  of  auto-antibodies 
against different citrullinated antigens.2 Despite the 
excellent performance of these immunoassays, anti-
cyclic  citrullinated  peptide  antibodies  (anti-CCP1, 
2 and 3) provide a sensitivity less than that of rheu-
matoid  factor  (RF)  ∼55%–60%  and  many  cases 
with clinically definitive RA lack these antibodies. 
Additionally,  the  correlation  of  anti-CCP  with  RA 
disease activity yielded conflicting results.3
Although  the  peptide/antigen  used  in  the  first 
generation anti-CCP1 test has been clearly described. 
The antigen used for the second and third generation 
anti-CCP tests (anti-CCP2 and anti-CCP3) have been 
described by the manufacturer as being confidential. 
The confidential nature of the antigen used in these 
tests has its limitations. We do not know whether these 
anti-CCP tests measure true auto-antibody reactivity 
or not. This provides a cautionary note for clinicians 
interpreting the anti-CCP test results, since the exact 
nature of what is being tested has not been subjected to 
external scrutiny. Likewise, basic scientists in this field 
should remember that although measurement of CCP 
reactive antibodies may be useful as RA biomarkers, 
the anti-CCP2 and anti-CCP3 tests do not necessarily 
measure true auto-antibodies in RA patients, since the 
peptides used in these commercial anti-CCP assays 
may not contain bona fide auto-antigens.4
Antibodies to citrullinated vimentin are referred 
to as anti-Sa, after the index patient, Savoie.¹ The Sa 
antigen is the starting point for the development of 
an enzyme-linked immunosorbent assay (ELISA) to 
detect  mutated  citrullinated  vimentin  (anti-MCV), 
which was developed few years later. Vossenaar et al5 
demonstrated  that,  antibodies  in  anti-Sa  positive 
RA  sera  bind  to  citrullinated  vimentin,  indicating 
that anti-Sa belongs to a group of antibodies against 
citrullinated  proteins.        Anti-Sa  reactivity  has  been 
shown  to  consist  at  least  partially—of  anti-MCV. 
However, the patterns of reactivity for anti-Sa and anti-
vimentin are not identical to that of anti-CCP antibod-
ies. Thus it should be of interest to investigate whether 
analysis  of  immunoreactivity  with  citrullinated 
vimentin adds to the information concerning the diag-
nosis and prognosis of RA gained from the anti-CCP 
assay or not.6
A recently developed ELISA for the quantification 
of anti-MCV antibodies was used to assess its clinical 
and predictive values in RA patients.
Despite the fact that any joint can be affected in RA 
patients, axial joints involvement seems to be a taboo 
issue in RA. Most literatures were concerned with the 
peripheral joints disease . Apophesyeal, costovertebral 
and  discovertebral  joints  can  be  affected  in  RA.7 
Narvaez et al8 reported that the cervical spine is the 
next region to be affected after the metacarpophalen-
gial joints in RA patients.
Axial  joints  affection  in  RA  has  its  definitive 
radiological characteristics that help to differentiate it 
from that of seronegative spondyloarthritis (SpA). In RA, 
the cervical spine is the most frequently affected region 
of the spine followed by the dorsal and the lumbar regions 
[descending marsh in contrary to the ascending marsh 
in SpA]. No boney calcinosis, ankylosis, new bone 
formation, osteophytes or syndesmophytes; the hall-
mark of SpA. There are apophyseal joints erosions, 
disc  space  narrowing,  endplate  sclerosis,  multiple 
vertebral subluxations [malalignment] at the atlanto-
axial, sub-axial and lumbar regions. Osteoporosis is a 
common finding in RA spine in contrary to new bone 
formation,  calcification  and  bamboo  spine  in  SpA. 
Degenerative disk disease may supervene and contrib-
ute to the severity of cervical spine involvement and to 
the development of dislocation.9
Aim of the study
Our  aim  was  to  investigate  the  diagnostic  and 
prognostic value of anti-MCV and its correlation—if 
any—with  disease  activity,  peripheral  and  axial 
skeleton affection in RA patients.
patients and Methods
study population
A total of 123 patients with different rheumatic diseases 
were enrolled in a prospective two-year study: 64 RA Anti-mutated citrullinated vimentin in rheumatoid arthritis
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patients and 59 patients with other rheumatic diseases as 
controls; (29 with systemic lupus erythematosus (SLE), 
8 with spondyloarthritis (SpA), 6 with   undifferentiated 
connective tissue disease, 6 with 1ry antiphospholipid 
syndrome and 10 patients with gouty arthritis).
All RA patients fulfiled the traditional American 
College of Rheumatology ACR criteria10 and the new 
rheumatoid arthritis diagnostic criteria recently relea-
sed by ACR/Europian league against Rheumatism-
EULAR panel.11 Patients were either attending the 
outpatients’  clinic  or  they  were  inpatients  in  the 
Rheumatology  Department,  Ain  Shams  University 
Hospital, between January 2007 and July 2009; they 
were  followed  up  for  two  years  with  occasional 
admissions (disease flares or complications).
All patients gave informed consent to participate 
in the study, which was approved by the Ain Shams 
Medical ethics committee. Patients underwent; clini-
cal assessment of disease activity by full history tak-
ing general and local examinations, measurement of 
the 28-joint count of tender and swollen joint’ with 
calculation of the disease activity score (DAS-28) for 
each RA patient by DAS-28 score calculator.12
•	 DAS-28  3.2 = inactive disease.
•	 DAS-28 . 3.2  5.1 = moderate disease activity.
•	 DAS-28 . 5.1 = severe disease activity.
The  response  to  therapy  and  remissions  were 
determined  according  to  the  EULAR-28  response 
criteria (DAS-28  2.6).13
Clinical  data  were  recorded  for  each  patient: 
Swo  llen joint count (SJC), tender joint count (TJC), 
duration of morning stiffness, fever and systemic upset 
symptoms. At baseline, 52 RA patients (81%) were 
treated by different combinations of disease modify-
ing anti-rheumatic drugs (DMARDs), with or without 
corticosteroids, in absence of any information about 
their serological status regarding anti-MCV reactivity.
Laboratory method
samples and analysis
After an overnight fast, 5 mL of venous blood was 
withdrawn from each patient; 2 mL was put in a test 
tube  with  EDTA  anticoagulant  for  complete  blood 
count (CBC) on a Sysmex KN21 (Beckman Instrument 
Incorporation,  California,  USA).  Erythrocytes  sedi-
mentation rate (ESR) was measured by Westergreen 
method as cited in clinical laboratory methods. The 
other 3 mL was put in a clean plain test tube; after 
  centrifugation,  the  separated  serum  was  stored 
at—20 °C until use. C-reactive protein (CRP) was 
tested by the Latex method, following standard clini-
cal laboratory methods. Rheumatoid factor (RF) titer 
was  assayed  according  to  (Orgentec  Diagnostika 
GmbH Germany).14 Anti-MCV IgG immunoglobins’ 
assay was performed at the study endpoint- by the 
kits and the standards of ORGENTEC Diagnostika 
(GmbH Germany).1
radiological method
Plain X-ray films were performed on the small joints 
of the hands, wrists, feet, cervical and lumbosacral 
regions in all RA patients at baseline (n = 64) and after 
two years (n = 52). These films were examined by 
expert radiologists. The simplified erosion narrowing 
score  (SEN  score)  method  was  used  in  assessing 
the peripheral joints (narrowing/erosion) at 28 joint 
regions  and  a  score  was  given  for  each  patient.
Radiological progression was defined as an increase 
in the SEN score from the baseline to endpoint that 
was greater than the median value for each patient.15
Magnetic resonance imaging (MRI) scanning was 
performed at the MRI unit of the Delta Radiology 
center on the cervical and lumbo-sacral regions to 22 
RA patients who were found to be symptomatic; [neck 
pain,  backache,  stiffness,  limitation  of  movement, 
nerve root compression, sciatica with motor and/or 
sensory dysfunctions] and for those suspected to have 
atlantoaxial subluxation by plain X-ray films.
The MRI scans involved antroposterior and lateral 
projections for the cervical and lumbar spine. Scans 
were performed on the cervical region from C1 to 
C7 and on the lumbar region from L1 to L5 vertebral 
bodies, using the Siemens machine (Somatom model) 
set to an 0.23 open system using a phased array cervical 
coil  and  spinal  coil.  In  some  cases,  we  included 
extension and flexion to the cervical region, and in 
other scans were undertaken following intravenous 
contrast material administration by manual injection 
at a dose of 0.2 mL/kg.
statistical method
The data was analyzed on an IBM computer using   
SPSS  (version  12).  Quantitative  variables  were Mansour et al
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described as mean, standard deviation (SD) and range. 
Qualitative variables were described as number and 
percentage. The Chi-square test was used to compare 
qualitative variables between groups. The Kruskall-
Wallis  test  was  used  instead  of  ANOVA  in  non-
  parametric  data  (SD  .  50%  mean).  Spearman’s 
correlation test was used to rank different variables 
against each other. Unpaired student’s t-test was used 
to compare quantitative variables in parametric data 
(SD , 50% mean). Receiver operator characteristic 
curve (ROC) was drawn to find out the best cut-off 
value of anti-MCV in diagnosing RA and to test for 
its statistical efficacy. P-value . 0.05 was considered 
insignificant, P , 0.05 was significant and P , 0.01 
was highly significant.
Results
After anti-MCV testing, RA patients were classified 
into anti-MCV positive group (n = 51) and anti-MCV 
negative group (n = 13) for statistical comparison.
According  to  Student’s  t-test;  there  was  sig- 
nificantly higher ESR, CRP, DAS-28 and SEN scores 
in anti-MCV positive than negative patients, at 95% CI 
in spite of non-significant differences in the RF titers 
between both groups. The Chi-square test revealed a 
significantly higher incidence of axial skeleton affec-
tion in anti-MCV positive group (Table 3).
On  comparing  baseline  and  endpoint  data  of 
anti-MCV positive patients by the Student’s t-test, 
there  was  statistically non-significant  improvement 
in  inflammatory  markers  of  disease  activity  (CRP, 
DAS-28 and VAS). Although most patients were on 
regular combinations of disease modifying anti-rheu-
matic drugs (DMARD) therapy. Importantly, signifi-
cantly higher SEN scores were seen after two years 
in anti-MCV positive patients, indicating significant 
radiological progression (Table 4).
The Student’s t-test showed significant improve- 
ment in DAS-28 and the RF titer in anti-MCV nega-
tive RA patients after two years (P = 0.003 and 0.023, 
respectively),  with  non-significant  progression  in 
radiological  damage  to  the  peripheral  joints  (SEN 
score, ESR or CRP) (Table 5).
Spearman’s  correlation  test  ranks  the  anti-MCV 
titer against different variables. The anti-MCV titer 
was found to be positively correlated with markers of 
disease activity: (DAS-28, CRP, VAS, SEN score and 
with axial joint involvement by MRI). However, it was 
not correlated either with ESR or RF titer (Table 6).
Multivariate analysis at 95% CI was done to study 
the influence of different disease parameters on the 
radiological outcome of RA patients at two years. It 
was found to be mostly affected by CRP and anti-MCV 
titers (Table 7).
The best cut-off value for the anti-MCV test was 
found  at  20.5  U/L. The  area  under  the  curve  was 
0.893 at the 95% CI, conferring an odds ratio of 32.5. 
Sensitivity was 79.6% and specificity was 96.6% in 
diagnosing RA patients (Table 8).
Table 1. Methodology of the MrI scans on the cervical and lumbar spine.
cervical spine: sagittal fast spin echo Lumbar spine: sagittal fast spin echo
T1 W1 T2 W1 Axial gradient echo T1 W1 T2 W1 Axial T2 W1
rT 550 3900 95 600 4000 4730
eT 12 127 47 30 127 117
sL 4 mm 4.5 mm 4.5 mm 4 mm 4 mm 5 mm
FOV 280 × 280 220 × 220 220 × 220 320 × 320 320 × 320 240 × 240
Abbreviations: RT, repetition time; ET, echo time; SL, slice thickness; FOV, field of view; Unit = matrix size.
Table 2. Demographic, laboratory and clinical data of all 
rA patients (n = 64) at study baseline (two years ago).
Mean ± sD Range
Age (years)   41.58 ± 11.44 (18–55)
Sex (45♀, 19♂) –
DD (years)   5.58 ± 3.7 (3.0–15)
esr (1st h)    43.27 ± 14.25 (30–95)
CrP (mg%)   25.62 ± 27.4 (4.0–45)
DAs-28   4.18 ± 1.73 (1.8–6.3)
VAs/100 mm   51.25 ± 20.09 (30–100)
sen score    17.31 ± 9.06 (10–55)
rF titer (U/mL) 106.02 ± 143.12 (12–305)
*Anti-MCV titer (U/mL) 114.45 ± 214.57 (11–329)
Abbreviations: DD, disease duration; VAs, visual analogue scale.*Anti-
MCV testing was performed for all rA patients only at the study endpoint.Anti-mutated citrullinated vimentin in rheumatoid arthritis
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MrI results of the cervical spine
Seventeen of the 22 (77%) RA patients were found 
to have different forms of cervical spine lesions, 
three (13%) were found to have atlantoaxial sub-
luxation due to typical destruction of the atlanto-
axial complex by pannus tissue. The bone segment 
of  the  cervical  spine  showed  destruction  of  the 
apophesyeal  joints  with  narrowed  disc  spaces  in 
five patients (22%). Minor indentation of the dura 
opposite the disc spaces was found in 11/22 (50%); 
this was a frequent finding as a consequence of disc 
bulging and/or osteophyte formation of the cervical 
bodies due to superadded degenerative disc disease. 
Increased signal intensity in the spinal cord was 
found in 4/22 (18%) patients, which was adjusted 
to the sites of compression suggested by edema and 
inflammation of the cord (mylopathy). Two cases 
(9%) showed superficial and deep enhancements of 
the pannus.
MrI results of the lumbar spine
Grade  0  =  normal  findings  (14/22,  63%).  Grade 
I = shows signal intensity changes at the vertebral end 
plates (8/22, 36%). Grade II shows irregular margins of 
the vertebral bodies with change of the signal intensity 
(4/22, 18%). Grade III = collapse of the intervertebral 
discs or the vertebral bodies ± vertebral subluxation 
(two cases, 9%), there was collapse of L3/4 vertebral 
bodies and vertebral subluxation spondylolithesis of 
L4 over L5 vertebrae with narrowed L4/L5 disc space.
Discussion
Since the switch in paradigm in treatment of RA from 
retarding the start of specific therapy to early aggressive 
and sometimes biological therapy, the development 
of the disease can now be effectively controlled or 
even be halted.17 In this context, it is of a particular 
importance to identify a sensitive diagnostic marker 
which permits early definitive diagnosis of RA.
Table 3. Comparison between anti-MCV positive and negative rA patients at study endpoint.
Anti-McV +ve 
(n = 51) 
mean ± sD
Anti-McV −ve 
(n = 13) 
mean ± sD
2-tailed 
significance 
(P,)
Age (years)    42.32 ± 11.57 40.12 ± 11.5 0.992
DD (years)    5.91 ± 3.25    4.61 ± 2.32 0.453
esr (1st h)    48.77 ± 11.25 28.46 ± 10.54 0.001*
CrP (mg%)    21.80 ± 29.83    9.0 ± 3.05 0.035*
DAs-28    4.24 ± 1.14    2.82 ± 0.35 0.05*
VAs/100 mm    61.45 ± 11.40 55.76 ± 9.54 0.901
sen score     20.22 ± 8.85    9.46 ± 2.78 0.05*
Flares per year (n = )    4.15 ± 1.32    2.31 ± 0.05 0.05*
rF titer (U/L)    59.91 ± 155.7 41.69 ± 73.45 0.422
Anti-MCV titer (U/L) 153.62 ± 240.4 19.00 ± 5.59 0.000+
Axial joints/Chi-square test 16/51 (31%) 1/13 (7%) 0.044*
+Significant by welch statistics due to absence of variance homogeneity.
Table 4. Comparison between baseline and endpoint data of anti-MCV positive rA patients.
Anti-McV positive (n = 51)
Baseline 
mean ± sD
endpoint 
mean ± sD
sig. (2-tailed) 
(P,)
esr (1st h)  52.57 ± 13.07 48.77 ± 11.25 0.03*
CrP (mg%) 27.57 ± 6.38 21.80 ± 29.83 0.106
DAs-28    5.24 ± 1.29    4.24 ± 1.14 0.350
VAs/100 mm 65.76 ± 12.37 61.45 ± 11.40 0.781
sen score  14.45 ± 7.97 20.22 ± 8.85 0.05*
rF-titer (U/L) 64.39 ± 113.7 59.91 ± 155.7 0.322Mansour et al
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Recently, a new diagnostic criteria for RA has been 
developed by the EULAR/ACR panel. Thist included 
for the first time—the anti-citrullinated peptide anti-
bodies (ACPA) as serological marker for the diag-
nosis of RA. In spite of the improvement that has 
been achieved in the diagnosis of RA by including 
these antibodies in the diagnostic criteria yet, the low 
sensitivity of the test (40%–50%) in most published 
cohorts indicates that a negative anti-CCP test does 
not exclude the disease. The sensitivity of anti-CCP2 
ranged from 25 to 58%.Very low sensitivity of anti-
CCP2 in some ethnic groups has also been reported. 
Accordingly, ethnical variations should be considered 
in evaluating the value of any anti-citrullinated protein 
antibodies test currently available in the market.18–23
In  the  present  study,  (123)  Caucasian  patients 
with different rheumatic diseases, were enrolled in 
a  prospective  study. All  were  tested  by  the  newly 
developed  ELISA  for  the  presence  of  anti-MCV: 
Out of 64 RA patients, 51 (79.6%) tested positive for 
anti-MCV (mean ± SD, 153.62 ± 240.4), as did 4/29 
SLE patients (13.7%), 1/8 SpA patients (12.5%) and 
2/6 (33%) undifferentiated connective tissue disease 
patients.  None  of  the  anti-phospholipid  syndrome 
or  gouty  arthritis  patients  tested  positive  for  the 
anti-MCV antibodies. The area under the curve was 
0.893  at  the  95%  CI,  conferring  an  odds  ratio  of 
23.5  in  diagnosing  RA  with  a  negative  odds  ratio 
of 0.21. Anti-MCV sensitivity and specificity were 
79.6% and 96.6%, respectively, at cut-off value 20.5 
U/L. In agreement with our results; Egerer et al24 who 
studied  anti-MCV  antibodies  in  1151  RA  patients, 
found that anti-MCV antibodies have the same spec-
ificity as anti-CCP antibodies but with much better 
sensitivity (82% versus 72%). Similarly, Mathsson 
et al25 and Gross et al17 concluded that the anti-MCV 
assay extends the diagnostic spectrum for RA with 
higher  sensitivity  and  prognostic  value  concerning 
radiological  progression  than  anti-CCP  antibodies 
(71% versus 58%, respectively).
In  this  study,  a  positive  anti-MCV  test  in  a 
non-rheumatoid  arthritis  patients;  did  not  abso-
lutely contradict the specificity of the test, as most of 
these  patients  had  rheumatoid-like  inflammatory 
Table 6. Correlations of anti-MCV titer with different disease 
parameters.
Anti-McV titer (U/L)
spearman’s r sig. (2-tailed) 
(P ,) 
esr (1st h)  0.331 0.367
CrP (mg/dl) 0.651 0.021*
rF titer (U/L) 0.460 0.212
DAs-28 0.802 0.001*
VAs/100 mm 0.847 0.005*
sen score  0.821 0.003*
Axial joints by MRI  0.637 0.042*
Table 7. Multivariate analysis for the radiological outcome 
at 24 months.
Regression 
coefficient 
(β)
“t” Significance 
P , 0.05 
Age (years) −0.031 −0.366 0.716
Sex 0.124 1.280 0.208
DD (years) −0.42 −0.456 0.651
esr (1st h)  −0.093 −0.522 0.605
CrP (mg%) −0.132 −1.184 0.034*
rF titer (U/L) 0.158 1.635 0.227
DAs-28 0.216 0.962 0.342
VAs/100 mm 0.290 1.276 0.210
Anti-MCV  
titer (U/L)
0.634 6.389 0.001*
Table 5. Comparison between baseline and endpoint data of anti-MCV negative rA patients.
Anti-McV negative (n = 13)
Baseline 
(mean ± sD)
endpoint 
(mean ± sD)
sig. (2-tailed) 
(P,)
esr (1st h)  33.15 ± 12.80 28.46 ± 10.54 0.012
CrP (mg%) 10.53 ± 2.53    9.00 ± 3.05 0.284
DAs-28    3.80 ± 0.40    2.82 ± 0.35 0.003*
VAs/100 mm 60.76 ± 7.65 55.76 ± 9.54 0.351
sen score     7.69 ± 3.06    8.46 ± 2.78 0.063
rF titer (U/L) 57.34 ± 56.76 41.69 ± 73.45 0.023*Anti-mutated citrullinated vimentin in rheumatoid arthritis
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polyarthritis: Jaccaud’s arthropathy (JA) was present 
in the four SLE patients who tested positive for anti-
MCV. Patients with undifferentiated connective tissue 
disease who were found to have positive anti-MCV 
tests fulfilled the ACR criteria for RA during follow-
up. However, no explanation could be given for the 
positive anti-MCV test in one patient with ankylos-
ing spondylitis. In agreement with our results, Galvao 
et al26 found that a positive anti-MCV test was found 
in 10.4% of SLE patients (five cases), all of which 
were found to have Jaccaud’s arthropathy (JA). By 
contrast,  anti-CCP  was  found  in  six  SLE  patients, 
with no difference between those with or without JA 
(P . 0.05).
In  the  present  study,  anti-MCV  positive  RA 
patients  were  found  to  have  a  more  aggressive 
disease course (P , 0.05) with a higher number of 
flares per year (4.15 vs. 2.3) and poor disease control 
(a non-significant improvement in DAS-28 in spite 
of good complaint on combined DMARD therapy) 
than anti-MCV negative patients. Additionally, they 
were found to have progressive radiological damage 
with  significant  progression  in  SEN  scores  over 
time than the anti-MCV negative patients (20.22 vs. 
9.46), who were found to have a more benign disease 
course  with  significantly  lower  DAS-28  scores, 
and significant improvement in SJC, TJC and ESR 
with DMARD therapy. Significant positive correla-
tions have been found between an anti-MCV titer 
withDAS-28,  SEN  scores, VAS  and  CRP,  but  not 
with ESR or RF titer.
Innala  et  al27  concluded  that  anti-MCV  titer 
was  significantly  correlated  with  DAS-28,  SJC 
and ESR. In a three-year follow-up study of 427 
RA patients, Keskin et al28 found that patients with 
active  RA  were  found  to  have  higher  anti-MCV 
titers  than  patients  with  inactive  disease,  while, 
the anti-CCP titer failed to show this correlation (a 
non-significant difference in anti-CCP titer between 
patients with active or inactive disease). Evidence 
from diagnostic case-control studies suggests that 
the anti-MCV test may be used as an alternative to 
the anti-CCP test.6
In our study, multivariate analysis for the radiological 
outcome at 24 months revealed that anti-MCV titer and 
CRP were the most implicated in radiological damage 
of both peripheral and axial joints. In concordance 
with our results, Syversen et al29 studied the correlation 
between the anti-MCV titer and radiological damage 
in a 10-year follow-up study on 238 RA patients; how-
ever, they studied the correlation only with peripheral 
joints, assessed by the modified sharp score of Van 
Der Hijde.30 They concluded that a positive anti-MCV 
titer increased the odds of radiographic progression 
by 7.3 (95% CI: 3.2–16.5) compared to odds of 5.7 
for positive anti-CCP test. Anti-MCV positivity was 
Table 8. Diagnostic effectiveness of the anti-MCV test.
Anti-McV titer best cut-off value = 20.5 U/L
sensitivity  79.6%
Specificity  96.6%*
PPV  96.22%, 95% CI = 87.24%
nPV  81.42%, 95%, CI = 87.24%
Accuracy  87.80%
Positive DLr  23.50 (+ve odds ratio)
negative DLr  0.21 (−ve odds ratio)
Prevalence  52.03%
Pre-test odds/probability 1.08
post-test odds +ve  25.49
TPFn ratio 3.9231
Abbreviations: PPV, positive predictive value; nPV, negative predictive 
value; DLr, diagnostic likelihood ratio (odds ratio); TPF n,	the proportion 
of true positives to false negatives for the test condition; Pre-test odds/
probability, the odds/probability of the condition (prevalence) in the whole 
community.16 
*Out of the 29 sLe patients; four were tested positive for the anti-MCV 
test (13.7%), as did one of the eight SpA patients and two of the six 
undifferentiated  CT  disease  patients,  but  none  of  the  gouty  arthritis 
patients.
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Figure 1. rOC (red line) assessing the validity of the anti-MCV test in 
diagnosing rA. The area under the curve was 0.893 at the 95% CI.Mansour et al
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associated  with  an  average  increase  in  total  sharp 
score. Interestingly, they found that a positive anti-
MCV test was associated with boney erosions rather 
than joint space narrowing (cartilage damage). How-
ever, positive anti-CCP was associated with joint space 
narrowing.
Few reports were found regarding the axial joint 
affection in RA, as most were concerned with the 
study of the peripheral joints. In the present study—as 
a novelty out of 22 RA patients who underwent MRI 
scans on the cervical and lumbar regions, 17 (77%) 
were found to have cervical joint damage, ranging 
from  apophesyeal  joints  erosion  and  disc  space 
narrowing to atlantoaxial subluxation. Involvement 
of  the  lumbo-sacral  regions  was  significantly  less 
frequently  observed  (8/22,  36%;  P  ,  0.05);  this 
involvement  ranged  from  irregular  margins  of  the 
vertebral bodies with changed signal intensity to col-
lapsed intervertebral discs, disc space narrowing and 
lumbar vertebral subluxation.
In agreement with Sakai et al9 we have found that 
axial joint involvement in RA patients was significantly   
associated  with  aggressive  peripheral  joints  erosive 
disease and high disease activity scores, but they didn’t 
test or correlate this with the anti-MCV titer as we did. 
Importantly, in our study, all RA patients with lumbo-
sacral joint affection were found to have cervical joint 
involvement, but the reverse was not true.
Narvaez  et  al8  studied  the  correlation  between 
cervical spine involvement by MRI and neurological 
manifestations in 41 RA patients with symptomatic 
Figure 2. Sagittal fast spin-echo MRI of the cervical spine in an RA patient (a 51-year-old woman who had suffered RA for 31 years) with superficial and 
deep enhancement. A) (T1-weighted) and c- (T2-weighted) images show; stenoses at levels C1–2 and C3–4, mostly caused by pannus and subluxation 
at level C1–2 and by discopathy and ligamentum flavum hypertrophy. B) (gadolinium-enhanced T1-weighted image) shows; superficial enhancement 
lining the cerebrospinal fluid (arrow 1) and enhancement involving deeper structures. Deep enhancing tissue is recognized as bone and pannus tissue on 
C1–2 (arrow 2), as a disc on anterior levels (arrow 3), level C3–4 (arrow 4). Ligamentum flavum and interspinal ligaments are enhanced at the posterior 
levels (arrow 5). Deep enhancement coincides mostly with narrowing of the spinal canal at these levels. note enhancement of the ligamentum nuchae 
(arrow 6).
AB
Figure 3. A) Lateral radiograph of the lumbar spine in a male rA patient 
shows height reduction and narrowing of the intervertebral disk spaces, 
sclerosis of the endplates at L4–5 and erosion (arrow) of the superior 
endplate of L5. B) sagittal T1-weighted fast spin-echo MrI reveals ero-
sive defects of the inferior endplate (arrow) of L4 and superior endplate 
of L5, as well as signal loss in the surrounding bone marrow. Anti-mutated citrullinated vimentin in rheumatoid arthritis
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cervical  joint  affection. They  concluded  that  cervi-
cal spine MRI appears to be a valuable method to 
identify RA patients at risk of developing neurological 
dysfunctions. Kauppi et al31 evaluated the five-year 
incidence  of  cervical  spine  involvement  in  patients 
with  early  RA  (n  =  199),—in  agreement  with  our 
    findings- they concluded that higher RA DAS-28 scores 
and poor health assessment questionnaire results were 
significantly associated with cervical spine involve-
ment and atlantoaxial subluxation. They added that 
RA patients on single DMARD therapy and with poor 
disease control were found to be more liable to cervi-
cal joint affection than those on combined DMARDs 
therapy and tight disease control.
Conclusion and recommendations
Anti-MCV  antibodies  can  be  regarded  as  a 
promising  diagnostic  and  prognostic  marker  in  RA 
patients with high sensitivity and specificity. Anti-MCV 
testing would help in early definitive diagnosis of RA 
and may identify a subset of RA patients with aggres-
sive early erosive disease with high disease activity 
scores and poor disease control. Testing for these anti-
bodies early in the disease can guide the choice of ini-
tial therapy, reserving aggressive regimens for those 
with positive anti-MCV titers and high disease activity 
scores who are suspected to have an aggressive early 
erosive disease course, in attempts to improve RA dis-
ease control and outcome. The axial skeleton can be 
affected in RA patients, especially the cervical region. 
MRI scanning of the spine is a sensitive method for 
detecting early axial joints affection in RA patients.
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